Company / Share Buybacks
Vertex Pharmaceuticals Share Buybacks History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Share Buybacks
$2.0B
FY2025
5-year range
$0 / $2.0B
FY2021-FY2025
Trend
+71.4%
vs FY2024
Sector context
#5 of 48
Health Care
What the data says
Among 48 Health Care companies, Vertex Pharmaceuticals is in the top 10% for share buybacks. Share Buybacks has increased for 3 consecutive years, from $0 in FY2022 to $2.0B in FY2025.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +30.2%. Top quartile in the Health Care sector.
Improved from $428M to $2.0B over the past 2 years.
Health Care sector context is included.
Share Buybacks over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +30.2%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 48This company $2.0B Sector average $611.9M
▼
+229.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +30.2%, indicating consistent growth.
- In FY2025, share buybacks increased 71.4% year-over-year.
- Ranks #5 out of 48 companies in the Health Care sector.
- Lowest share buybacks in the period was in FY2022.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Share BuybacksValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +71.4% |
| FY2024 | $1.2B | +175.3% |
| FY2023 | $427.6M | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $1.4B | +164.4% |
| FY2020 | $539.1M | +189.8% |
| FY2019 | $186.0M | -46.9% |
| FY2018 | $350.0M | - |
| FY2017 | $0 | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026